aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in Watertown, United States, Enanta Pharmaceuticals is a biotechnology company dedicated to the research, development, and creation of small molecule drugs targeting viral infections and liver diseases. The company's core mission is to discover and develop highly differentiated therapeutics through innovative chemistry, addressing areas of high unmet medical need. Enanta's product portfolio includes treatments for hepatitis C, respiratory syncytial virus (RSV), and non-alcoholic steatohepatitis (NASH), among others.
Enanta Pharmaceuticals boasts a team of some of the brightest minds in the pharma and biotech sectors. The company has garnered significant attention and investment from notable figures in the industry. Its key achievements include the successful development of several antiviral therapies that have made substantial impacts on patient care. Enanta's commitment to scientific excellence and bold innovation has positioned it as a leader in creating novel medicines, significantly impacting the treatment landscape for viral and liver diseases.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals, Drugs
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Enanta Pharmaceuticals founded?
Enanta Pharmaceuticals was founded in 1995.
Where is Enanta Pharmaceuticals’s headquarters located?
Enanta Pharmaceuticals’s headquarters is located in Watertown, MA, US.
When was Enanta Pharmaceuticals’s last funding round?
Enanta Pharmaceuticals’s most recent funding round was for $9.2M (USD) in September 2013.
How many employees does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 160 employees as of Feb 6, 2024.
How much has Enanta Pharmaceuticals raised to-date?
As of July 05, 2023, Enanta Pharmaceuticals has raised a total of $84.6M (USD) since Sep 3, 2013.
Add Comparison
Total Raised to Date
$84.6M
USD
Last Update Sep 3, 2013
Last Deal Details
$9.2M
USD
Sep 3, 2013
Post Ipo Equity
Total Employees Over Time
160
As of Feb 2024
Enanta Pharmaceuticals Address
400 Talcott Avenue
Watertown,
Massachusetts
02472
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts